JP2009517405A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009517405A5 JP2009517405A5 JP2008542537A JP2008542537A JP2009517405A5 JP 2009517405 A5 JP2009517405 A5 JP 2009517405A5 JP 2008542537 A JP2008542537 A JP 2008542537A JP 2008542537 A JP2008542537 A JP 2008542537A JP 2009517405 A5 JP2009517405 A5 JP 2009517405A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- human
- binds
- protein
- antibody according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101001010621 Homo sapiens Interleukin-21 Proteins 0.000 claims description 8
- 210000004408 hybridoma Anatomy 0.000 claims description 7
- 108010074108 interleukin-21 Proteins 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 5
- 102000036639 antigens Human genes 0.000 claims description 5
- 108091007433 antigens Proteins 0.000 claims description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 2
- 108090000790 Enzymes Proteins 0.000 claims description 2
- 229960002685 biotin Drugs 0.000 claims description 2
- 235000020958 biotin Nutrition 0.000 claims description 2
- 239000011616 biotin Substances 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 208000023275 Autoimmune disease Diseases 0.000 claims 3
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 3
- 125000000539 amino acid group Chemical group 0.000 claims 3
- 208000024908 graft versus host disease Diseases 0.000 claims 3
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 230000000890 antigenic effect Effects 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 201000005962 mycosis fungoides Diseases 0.000 claims 2
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims 2
- 230000004952 protein activity Effects 0.000 claims 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010013554 Diverticulum Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 1
- 206010021263 IgA nephropathy Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 238000004448 titration Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101710176384 Peptide 1 Proteins 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- 108091006020 Fc-tagged proteins Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74015405P | 2005-11-28 | 2005-11-28 | |
| US60/740,154 | 2005-11-28 | ||
| PCT/US2006/061277 WO2007111714A2 (en) | 2005-11-28 | 2006-11-28 | Il-21 antagonists |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012235520A Division JP6027849B2 (ja) | 2005-11-28 | 2012-10-25 | Ｉｌ−２１アンタゴニスト |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009517405A JP2009517405A (ja) | 2009-04-30 |
| JP2009517405A5 true JP2009517405A5 (enExample) | 2011-12-15 |
| JP5322653B2 JP5322653B2 (ja) | 2013-10-23 |
Family
ID=38541590
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008542537A Active JP5322653B2 (ja) | 2005-11-28 | 2006-11-28 | Ｉｌ−２１アンタゴニスト |
| JP2012235520A Active JP6027849B2 (ja) | 2005-11-28 | 2012-10-25 | Ｉｌ−２１アンタゴニスト |
| JP2015160266A Active JP6163520B2 (ja) | 2005-11-28 | 2015-08-17 | Ｉｌ−２１アンタゴニスト |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012235520A Active JP6027849B2 (ja) | 2005-11-28 | 2012-10-25 | Ｉｌ−２１アンタゴニスト |
| JP2015160266A Active JP6163520B2 (ja) | 2005-11-28 | 2015-08-17 | Ｉｌ−２１アンタゴニスト |
Country Status (10)
| Country | Link |
|---|---|
| US (5) | US20070122413A1 (enExample) |
| EP (3) | EP2567973B1 (enExample) |
| JP (3) | JP5322653B2 (enExample) |
| AU (1) | AU2006340750B2 (enExample) |
| CA (1) | CA2632215A1 (enExample) |
| DK (1) | DK1963369T3 (enExample) |
| ES (2) | ES2409835T3 (enExample) |
| PL (1) | PL1963369T3 (enExample) |
| PT (1) | PT1963369E (enExample) |
| WO (1) | WO2007111714A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6307024B1 (en) * | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| AU2006341398B9 (en) * | 2005-11-28 | 2012-02-02 | Zymogenetics, Inc. | IL-21 receptor antagonists |
| JP5322653B2 (ja) | 2005-11-28 | 2013-10-23 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−２１アンタゴニスト |
| WO2009047360A1 (en) * | 2007-10-11 | 2009-04-16 | Novo Nordisk A/S | Il-21 antibodies |
| JP5745274B2 (ja) | 2007-12-07 | 2015-07-08 | ザイモジェネティクス， インコーポレイテッド | 抗ヒトｉｌ−２１モノクローナル抗体 |
| WO2009132821A1 (en) * | 2008-04-28 | 2009-11-05 | Giuliani International Limited | Interleukin (il-21) binding proteins and methods of making and using same |
| ES2784830T3 (es) | 2008-10-08 | 2020-10-01 | Cambridge Entpr Ltd | Métodos para el diagnóstico y tratamiento de enfermedad autoinmune como consecuencia de esclerosis múltiple |
| JP5913103B2 (ja) | 2009-09-14 | 2016-04-27 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイトＴＨＥ ＲＥＧＥＮＴＳ ＯＦ ＴＨＥ ＵＮＩＶＥＲＳＩＴＹ ＯＦ ＣＯＬＯＲＡＤＯ，ａ ｂｏｄｙ ｃｏｒｐｏｒａｔｅ | 酵母ベースの免疫療法組成物を含む組合せ物及び被験者のスクリーニング方法 |
| JP2014506259A (ja) * | 2011-01-17 | 2014-03-13 | ノヴォ ノルディスク アー／エス | Ｉｌ−２１リガンド |
| WO2015089217A2 (en) | 2013-12-10 | 2015-06-18 | Bionz, Llc | Methods of developing selective peptide antagonists |
| SI2665486T1 (sl) | 2011-01-18 | 2020-07-31 | Bioniz, Llc | Sestavki za moduliranje aktivnosti gama-C-citokina |
| DE102011006809A1 (de) | 2011-04-05 | 2012-10-11 | Freistaat Bayern vertreten durch die Julius-Maximilians-Universität Würzburg | Verwendung eines Mittels aus Antikörpern und/oder Insulin-like growth factor-Antagonisten |
| CN103702721A (zh) * | 2011-05-31 | 2014-04-02 | 诺沃—诺迪斯克有限公司 | Il-21表位和il-21配体 |
| US9823246B2 (en) | 2011-12-28 | 2017-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescence enhancing plasmonic nanoscopic gold films and assays based thereon |
| WO2014005072A1 (en) | 2012-06-28 | 2014-01-03 | University Of Central Florida Research Foundation, Inc. | Methods and compositions for natural killer cells |
| WO2014205501A1 (en) | 2013-06-27 | 2014-12-31 | Monash University | Il-21 binding proteins and uses thereof |
| AR099625A1 (es) * | 2014-03-21 | 2016-08-03 | Lilly Co Eli | Anticuerpos de il-21 |
| EP3215846B1 (en) | 2014-11-05 | 2020-03-11 | Nirmidas Biotech, Inc. | Metal composites for enhanced imaging |
| WO2016096858A1 (en) * | 2014-12-19 | 2016-06-23 | Mabtech Ab | Composition, kit and method for inhibition of il-21 mediated activation of human cells |
| AU2015367224B2 (en) | 2014-12-19 | 2020-12-10 | Monash University | IL-21 antibodies |
| CA2978449A1 (en) | 2015-03-02 | 2016-09-09 | 180 Therapeutics Lp | Method of treating a localized fibrotic disorder using an il-33 antagonist |
| WO2017062685A1 (en) | 2015-10-09 | 2017-04-13 | Bioniz, Llc | Modulating gamma - c -cytokine activity |
| CA3018792C (en) * | 2016-03-31 | 2023-03-28 | Eli Lilly And Company | Il-21 antibodies and uses thereof |
| US20210324029A1 (en) * | 2017-04-07 | 2021-10-21 | Bioniz, Llc | Stable modulators of gamma-c-cytokine activity |
| GB201707048D0 (en) | 2017-05-03 | 2017-06-14 | King S College London | Expansion of gamma delta cells, compositions, and methods of use thereof |
| RU2667423C1 (ru) * | 2017-06-28 | 2018-09-19 | ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "ПраймБиоМед" | Мышиная гибридома ykl-39, клон 1b2 g4 - продуцент моноклонального антитела, обладающего специфичностью к цитоплазматическому антигену ykl-39 человека |
| CA3071376A1 (en) | 2017-08-03 | 2019-02-07 | Amgen Inc. | Interleukin-21 muteins and methods of treatment |
| AU2019207895A1 (en) | 2018-01-12 | 2020-06-18 | Amgen Inc. | Anti-PD-1 antibodies and methods of treatment |
| GB201818243D0 (en) | 2018-11-08 | 2018-12-26 | Gammadelta Therapeutics Ltd | Methods for isolating and expanding cells |
| CA3117895A1 (en) | 2018-11-08 | 2020-05-14 | GammaDelta Therapeutics Limited | Methods for isolating and expanding cells |
| WO2020227019A1 (en) | 2019-05-03 | 2020-11-12 | Bioniz, Llc | Modulating the effects of gamma-c-cytokine signaling for the treatment of alopecia and alopecia associated disorders |
| GB202006989D0 (en) | 2020-05-12 | 2020-06-24 | Gammadelta Therapeutics Ltd | Methods for isolating gamma delta t cells |
| GB202105113D0 (en) | 2021-04-09 | 2021-05-26 | Gammadelta Therapeutics Ltd | Novel method |
| GB202204926D0 (en) | 2022-04-04 | 2022-05-18 | Gammadelta Therapeutics Ltd | Method for expanding gammadelta T cells |
Family Cites Families (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2004A (en) * | 1841-03-12 | Improvement in the manner of constructing and propelling steam-vessels | ||
| US2005A (en) * | 1841-03-16 | Improvement in the manner of constructing molds for casting butt-hinges | ||
| US2006A (en) * | 1841-03-16 | Clamp for crimping leather | ||
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4603044A (en) | 1983-01-06 | 1986-07-29 | Technology Unlimited, Inc. | Hepatocyte Directed Vesicle delivery system |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| DE3785186T2 (de) | 1986-09-02 | 1993-07-15 | Enzon Lab Inc | Bindungsmolekuele mit einzelpolypeptidkette. |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| ATE140963T1 (de) | 1988-01-22 | 1996-08-15 | Zymogenetics Inc | Verfahren zur herstellung von sekretierten rezeptoranalogen |
| EP1997891A1 (en) | 1988-09-02 | 2008-12-03 | Dyax Corporation | Generation and selection of recombinant varied binding proteins |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5413923A (en) | 1989-07-25 | 1995-05-09 | Cell Genesys, Inc. | Homologous recombination for universal donor cells and chimeric mammalian hosts |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| DE69122313T2 (de) | 1990-06-21 | 1997-03-20 | Honeywell Inc | Auf variablem Horizont basierende adaptive Steuerung mit Mitteln zur Minimierung der Betriebskosten |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| WO1992022324A1 (en) | 1991-06-14 | 1992-12-23 | Xoma Corporation | Microbially-produced antibody fragments and their conjugates |
| AU3178993A (en) | 1991-11-25 | 1993-06-28 | Enzon, Inc. | Multivalent antigen-binding proteins |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| WO1995015982A2 (en) | 1993-12-08 | 1995-06-15 | Genzyme Corporation | Process for generating specific antibodies |
| DK1231268T3 (da) | 1994-01-31 | 2005-11-21 | Univ Boston | Polyklonale antistofbiblioteker |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6057127A (en) * | 1998-01-29 | 2000-05-02 | Heska Corporation | Equine Fc epsilon receptor alpha chain nucleic acid molecules and uses thereof |
| US7198789B2 (en) * | 1998-03-17 | 2007-04-03 | Genetics Institute, Llc | Methods and compositions for modulating interleukin-21 receptor activity |
| US6057128A (en) * | 1998-03-17 | 2000-05-02 | Genetics Institute, Inc. | MU-1, member of the cytokine receptor family |
| US20030003545A1 (en) * | 1998-05-29 | 2003-01-02 | Reinhard Ebner | Interleukins-21 and 22 |
| US20010023070A1 (en) | 1998-05-29 | 2001-09-20 | Reinhard Ebner | Interleukins-21 and 22 |
| EE05627B1 (et) | 1998-12-23 | 2013-02-15 | Pfizer Inc. | CTLA-4 vastased inimese monoklonaalsed antikehad |
| CN102406937A (zh) * | 1999-03-09 | 2012-04-11 | 津莫吉尼蒂克斯公司 | 新的细胞因子zalpha11配体 |
| US6307024B1 (en) | 1999-03-09 | 2001-10-23 | Zymogenetics, Inc. | Cytokine zalpha11 Ligand |
| US7135287B1 (en) | 1999-10-02 | 2006-11-14 | Biosite, Inc. | Human antibodies |
| AU2001253127A1 (en) | 2000-04-05 | 2001-10-23 | Zymogenetics Inc. | Soluble zalpha11 cytokine receptors |
| EP1332209B1 (en) | 2000-09-08 | 2009-11-11 | Universität Zürich | Collections of repeat proteins comprising repeat modules |
| DE10047189C1 (de) | 2000-09-23 | 2002-02-21 | Bosch Gmbh Robert | Verfahren zur Insassenklassifikation mit einer Sitzmatte im Fahrzeugsitz |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| DE60233888D1 (de) | 2001-11-05 | 2009-11-12 | Zymogenetics Inc | Il-21-antagonisten |
| US20040028665A1 (en) | 2002-01-08 | 2004-02-12 | Garner Bryan E. | Compositions and methods for inhibiting pathogenic growth |
| AU2003226141A1 (en) | 2002-03-27 | 2003-10-13 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method for treating cancer in humans |
| AU2003230834A1 (en) | 2002-04-09 | 2003-10-27 | Beth Israel Deaconess Medical Center, Inc. | Antagonists of il-21 and modulation of il-21-mediated t cell responses |
| US20040016010A1 (en) * | 2002-04-17 | 2004-01-22 | Marion Kasaian | IL-21 receptor knockout animal and methods of use thereof |
| PT1531850E (pt) | 2002-06-07 | 2012-05-07 | Zymogenetics Inc | Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos |
| AU2003251633A1 (en) | 2002-07-01 | 2004-01-19 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of | Il-21 as a regulator of immunoglobin production |
| KR20050037552A (ko) * | 2002-07-15 | 2005-04-22 | 와이어쓰 | Ｔ 헬퍼(ｔｈ) 세포 발생 및 기능을 조절하는 방법 및조성물 |
| EP1572131B1 (en) | 2002-10-08 | 2016-07-06 | Immunomedics, Inc. | Antibody therapy |
| US20070092485A1 (en) | 2002-11-15 | 2007-04-26 | Zymogenetics, Inc. | Cytokine zalpha11 ligand |
| JP3979276B2 (ja) * | 2002-11-29 | 2007-09-19 | 富士通株式会社 | 業務支援方法、業務支援装置、及びプログラム |
| KR101098897B1 (ko) | 2002-12-13 | 2011-12-26 | 지모제넥틱스, 인코포레이티드 | 원핵생물 숙주 내 ｉｌ-21 생산 |
| AU2003294930B2 (en) | 2002-12-23 | 2008-12-04 | Innate Pharma | Pharmaceutical compositions having an effect on the proliferation of NK cells and a method using the same |
| JP4914209B2 (ja) * | 2003-03-14 | 2012-04-11 | ワイス | ヒトｉｌ−２１受容体に対する抗体および該抗体の使用 |
| MXPA05010035A (es) * | 2003-03-21 | 2005-11-17 | Wyeth Corp | Tratamiento de desordenes inmunologicos usando agonistas de interleucina-21/receptor de interleucina-21. |
| WO2005037306A1 (en) | 2003-10-17 | 2005-04-28 | Novo Nordisk A/S | Combination therapy |
| JP4471721B2 (ja) | 2004-04-20 | 2010-06-02 | 独立行政法人産業技術総合研究所 | 抗インターロイキン２１受容体（ｉｌ−２１ｒ）抗体および本抗体を産生するハイブリドーマ |
| BRPI0510996A (pt) * | 2004-05-19 | 2007-12-04 | Wyeth Corp | métodos para melhorar um sintoma de um distúrbio atópico, e para tratar ou prevenir um distúrbio atópico em um paciente, métodos para modular a produção de igg e ige em uma célula, e nìveis relativos de ige e igg, composição farmacêutica, recipiente, métodos para avaliar um paciente tendo ou suspeito de ter um distúrbio atópico, e para avaliar um paciente quanto ao risco de um distúrbio atópico |
| US20060008844A1 (en) | 2004-06-17 | 2006-01-12 | Avidia Research Institute | c-Met kinase binding proteins |
| US20060039902A1 (en) * | 2004-08-05 | 2006-02-23 | Young Deborah A | Antagonizing interleukin-21 receptor activity |
| ITRM20040586A1 (it) * | 2004-11-29 | 2005-02-28 | Giuliani Spa | Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico. |
| WO2006105538A2 (en) | 2005-03-31 | 2006-10-05 | Centocor, Inc. | Methods and compositions for treating il-21 related pathologies |
| DK200501310A (da) | 2005-09-21 | 2005-10-01 | Novo Nordisk As | The invention relates to the treatment or prevention of autoimmune diseases and latent autoimmune diabetes in the adults |
| AU2006341398B9 (en) * | 2005-11-28 | 2012-02-02 | Zymogenetics, Inc. | IL-21 receptor antagonists |
| JP5322653B2 (ja) | 2005-11-28 | 2013-10-23 | ザイモジェネティクス， インコーポレイテッド | Ｉｌ−２１アンタゴニスト |
| JP5745274B2 (ja) | 2007-12-07 | 2015-07-08 | ザイモジェネティクス， インコーポレイテッド | 抗ヒトｉｌ−２１モノクローナル抗体 |
| WO2009132821A1 (en) | 2008-04-28 | 2009-11-05 | Giuliani International Limited | Interleukin (il-21) binding proteins and methods of making and using same |
| JP2014506259A (ja) | 2011-01-17 | 2014-03-13 | ノヴォ ノルディスク アー／エス | Ｉｌ−２１リガンド |
-
2006
- 2006-11-28 JP JP2008542537A patent/JP5322653B2/ja active Active
- 2006-11-28 EP EP12192046.6A patent/EP2567973B1/en not_active Revoked
- 2006-11-28 CA CA002632215A patent/CA2632215A1/en not_active Abandoned
- 2006-11-28 EP EP06850198.0A patent/EP1963369B1/en not_active Revoked
- 2006-11-28 WO PCT/US2006/061277 patent/WO2007111714A2/en not_active Ceased
- 2006-11-28 ES ES06850198T patent/ES2409835T3/es active Active
- 2006-11-28 DK DK06850198.0T patent/DK1963369T3/da active
- 2006-11-28 ES ES12192046.6T patent/ES2491118T3/es active Active
- 2006-11-28 EP EP14163892.4A patent/EP2805971A1/en not_active Withdrawn
- 2006-11-28 AU AU2006340750A patent/AU2006340750B2/en not_active Ceased
- 2006-11-28 PT PT68501980T patent/PT1963369E/pt unknown
- 2006-11-28 PL PL06850198T patent/PL1963369T3/pl unknown
- 2006-11-28 US US11/563,928 patent/US20070122413A1/en not_active Abandoned
-
2008
- 2008-07-24 US US12/179,003 patent/US7923539B2/en active Active
-
2011
- 2011-03-01 US US13/037,585 patent/US8222374B2/en active Active
-
2012
- 2012-06-08 US US13/492,315 patent/US9388241B2/en active Active
- 2012-10-25 JP JP2012235520A patent/JP6027849B2/ja active Active
-
2015
- 2015-08-17 JP JP2015160266A patent/JP6163520B2/ja active Active
-
2016
- 2016-06-09 US US15/177,914 patent/US20170037123A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009517405A5 (enExample) | ||
| WO2007111714B1 (en) | Il-21 antagonists | |
| CN110914304B (zh) | Cd96抗体、其抗原结合片段及医药用途 | |
| Shoham | Crystal Structure of an Anticholera Toxin Peptide Complex at 2· 3 Å | |
| WO2018177393A1 (zh) | B7-h3抗体、其抗原结合片段及其医药用途 | |
| EP3587452A1 (en) | Tim-3 antibody, antigen binding fragment thereof, and medicinal uses thereof | |
| CN110172097B (zh) | 一种抗结核分枝杆菌cfp-10蛋白的单克隆抗体及其应用 | |
| WO2019015282A1 (zh) | 靶向于白介素17a的抗体、其制备方法和应用 | |
| CN106188298B (zh) | 一种Vsig4纳米抗体及其抗原表位鉴定方法和应用 | |
| CN105801701B (zh) | 一种pcsk9抗体的重链和轻链可变区及其应用 | |
| JP2009517406A5 (enExample) | ||
| US11634481B2 (en) | B-cell epitope of Trichinella spiralis cysteine protease inhibitor, hybridoma cell line, monoclonal antibody and uses thereof | |
| JP7691234B2 (ja) | 抗体の抗原に対する親和性を向上させる方法及びその利用 | |
| CN112321709B (zh) | 澳洲坚果过敏原Vicilin特异性纳米抗体及其应用 | |
| CN114591432A (zh) | 抗TNFα的单域抗体及其用途 | |
| CN113929783A (zh) | 抗cd99蛋白单克隆抗体、细胞系及其制备方法和应用 | |
| CN116903739B (zh) | 一种抗s100b蛋白的抗体及其应用 | |
| CN114591423A (zh) | 新冠病毒n蛋白的特异性抗体及其制备方法与应用 | |
| TW201925233A (zh) | 抗體、用於在樣品中偵測或捕捉多肽的組成物以及在樣品中偵測或捕捉多肽的方法 | |
| CN116813765A (zh) | Rab8蛋白的特异性抗体及其制备方法与应用 | |
| CN114149503A (zh) | 抗tsh蛋白单克隆抗体、细胞系及其制备方法和应用 | |
| JP4059404B2 (ja) | 甲状腺機能を刺激する活性を持つ抗体 | |
| CN102660551B (zh) | 来源于抗CypA骆驼科动物的重链VHH抗体基因、编码多肽及其应用 | |
| CN113817055B (zh) | 抗Actin蛋白单克隆抗体、细胞系及其应用 | |
| CN113583125B (zh) | 抗体以及包含其的结合剂、免疫吸附材料及其应用 |